Table 1. Demographics and Disease... | American Society of Hematology

Table 1.

Demographics and Disease Characteristics

	Filgrastim	Placebo
No. of patients	259	262
Age
<50 yr	40%	44%
≥50 yr	60%	56%
50-70 yr	49%	49%
≥70 yr	11%	7%
Median (yr)	54	54
Range	16-89	16-88
Sex
Male	54%	54%
Female	46%	46%
ECOG status
0	24%	25%
1	59%	57%
2	17%	18%
FAB subtype
M0	3%	3%
M1	21%	23%
M2	27%	24%
M3^*	1%	3%
M4	24%	27%
M5	17%	13%
M6	4%	4%
M7	1%	2%
Not assessed	2%	1%
Cytogenetics^†
Favorable	3%	4%
Normal	37%	43%
Unfavorable	30%	29%
Not assessed	30%	24%

	Filgrastim	Placebo
No. of patients	259	262
Age
<50 yr	40%	44%
≥50 yr	60%	56%
50-70 yr	49%	49%
≥70 yr	11%	7%
Median (yr)	54	54
Range	16-89	16-88
Sex
Male	54%	54%
Female	46%	46%
ECOG status
0	24%	25%
1	59%	57%
2	17%	18%
FAB subtype
M0	3%	3%
M1	21%	23%
M2	27%	24%
M3^*	1%	3%
M4	24%	27%
M5	17%	13%
M6	4%	4%
M7	1%	2%
Not assessed	2%	1%
Cytogenetics^†
Favorable	3%	4%
Normal	37%	43%
Unfavorable	30%	29%
Not assessed	30%	24%

These patients had no previous treatment with ATRA.

Favorable: t(15,17), t(8,21) and inv(16). Unfavorable: monosomies 5, 7, trisomy 8, 11q(23), complex and multiple abnormalities.